This clinical trial is focused on studying a type of cancer called Mantle Cell Lymphoma, which is a rare form of non-Hodgkin’s lymphoma. The study is comparing two different treatment combinations for patients who have not received any prior treatment for this condition and are not eligible for a stem cell transplant. The first treatment combination includes Zanubrutinib (also known by its code name BGB-3111) and Rituximab. The second treatment combination includes Bendamustine and Rituximab. These medications are given to help manage the disease and improve patient outcomes.
The purpose of the study is to compare the effectiveness of these two treatment combinations. Patients participating in the study will receive one of the two treatment combinations. The study will monitor the patients over a period to see how well the treatments work in controlling the disease. The treatments are administered through infusions, which means they are given directly into the bloodstream through a vein. The study will also look at how long the treatments can keep the disease from getting worse and how they affect the patients’ overall health and quality of life.
Throughout the study, patients will be regularly assessed by healthcare professionals to track their progress and any side effects they may experience. The study aims to provide valuable information on which treatment combination is more effective for patients with Mantle Cell Lymphoma who cannot undergo a stem cell transplant. This information could help guide future treatment decisions for this condition.
Austria 
Belgium 
France 
Germany 
Ireland 
Italy 
Poland 
Portugal 
Romania 
Spain 
The Netherlands 